Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

NCT05866432 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Stage IV

Interventions

DRUG: Datopotamab deruxtecan

Sponsor

Medical University of Vienna

Collaborators

[object Object]